Related Experiment Video
Updated: May 30, 2026

An Enzyme- and Serum-free Neural Stem Cell Culture Model for EMT Investigation Suited for Drug Discovery
Published on: August 23, 2016
FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway
Filippos Kottakis1, Christos Polytarchou, Parthena Foltopoulou
1Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA.
Abstract:
The histone H3K27 methyltransferase EZH2 plays an important role in oncogenesis, by mechanisms that are incompletely understood. Here, we show that the JmjC domain histone H3 demethylase NDY1 synergizes with EZH2 to silence the EZH2 inhibitor miR-101. NDY1 and EZH2 repress miR-101 by binding its promoter in concert, via a process triggered by upregulation of NDY1. Whereas EZH2 binding depends on NDY1, the latter binds independently of EZH2. However, both are required to repress transcription. NDY1 and EZH2 acting in concert upregulate EZH2 and stabilize the repression of miR-101 and its outcome. NDY1 is induced by FGF-2 via CREB phosphorylation and activation, downstream of DYRK1A, and mediates the FGF-2 and EZH2 effects on cell proliferation, migration, and angiogenesis. The FGF-2-NDY1/EZH2-miR-101-EZH2 axis described here was found to be active in bladder cancer. These data delineate an oncogenic pathway that functionally links FGF-2 with EZH2 via NDY1 and miR-101.
Insights
The histone demethylase NDY1 and EZH2 collaborate to suppress miR-101, a key inhibitor of EZH2. This interaction drives oncogenesis and is active in bladder cancer, revealing a novel oncogenic pathway.
Area of Science:
- Epigenetics
- Molecular Oncology
- Cancer Biology
Background:
- Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase crucial in oncogenesis.
- The precise mechanisms underlying EZH2's role in cancer remain incompletely understood.
- MicroRNAs (miRNAs) are key regulators of gene expression implicated in cancer development.
Purpose of the Study:
- To elucidate the functional relationship between NDY1, EZH2, and miR-101 in oncogenesis.
- To identify the molecular pathway linking FGF-2, NDY1, EZH2, and miR-101.
- To investigate the activity of this pathway in bladder cancer.
Main Methods:
- Investigated the synergistic action of NDY1 and EZH2 on miR-101 promoter activity.
- Analyzed the binding of NDY1 and EZH2 to the miR-101 promoter.
- Examined the induction of NDY1 by FGF-2 and its downstream effects.
- Assessed the expression and activity of the FGF-2-NDY1/EZH2-miR-101 axis in bladder cancer samples.
Main Results:
- NDY1 and EZH2 cooperate to repress the transcription of miR-101 by binding its promoter.
- NDY1 upregulation triggers the concerted action of NDY1 and EZH2, leading to increased EZH2 levels and sustained miR-101 repression.
- FGF-2 induces NDY1 via CREB phosphorylation, mediating cellular effects on proliferation, migration, and angiogenesis.
- The identified FGF-2-NDY1/EZH2-miR-101-EZH2 axis is active in bladder cancer.
Conclusions:
- A novel oncogenic pathway involving FGF-2, NDY1, EZH2, and miR-101 has been delineated.
- This pathway links FGF-2 signaling to EZH2-mediated gene silencing through NDY1 and miR-101.
- The findings provide insights into the mechanisms of oncogenesis and potential therapeutic targets in bladder cancer.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
TGF - β Signaling Pathway
Mitogens and the Cell Cycle
Negative Regulator Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

